Venner Shipley welcomes Brookes IP Read more
  • Great Britain
  • Germany
  • France
  • China
  • Souht Korea


Biotechnology is one of Venner Shipley’s core disciplines and our attorneys are experienced in dealing with all aspects of IP in this field.

Our attorneys have expertise in drafting and prosecuting patent applications for technically complex biotechnology-related inventions. We appreciate how important it is not only to fully understand our clients’ technology, but also their business. This means gaining a thorough understanding of their commercial activities and aspirations, as well as those of their competitors and collaborators. To provide the best strategic advice, we work hard to develop a full understanding of our clients’ needs and appreciate that these are constantly changing and evolving.

Specific areas in which we have recently worked include:

  • antibodies
  • biochemistry
  • cancer therapeutics
  • diagnostics & therapeutics
  • DNA sequencing
  • enzymes
  • gene therapy
  • gene regulation
  • genomics & proteomics
  • immunology
  • molecular & cell biology
  • nucleic acids & protein products
  • stem cell technology
  • viral vectors

In addition to assisting our clients in obtaining patent protection in the biotechnology arena, we have vast experience in providing advice on potential infringement. We also prepare due diligence reports, especially for use in connection with company acquisitions and raising funding.

Oppositions and appeals

Valuable patents mean complex oppositions in the life sciences area, especially those relating to approved drugs, to methods for producing biotherapeutics and to platform technologies, such as CRISPR. Patents for production and platform technologies that are not restricted to a particular therapeutic agent can provide broad protection and are likely to be opposed by multiple parties, whether they are innovators or they are planning to produce biosimilars.

  • Digital Health Series – IP for Digital Health technologies (Part 2)

  • Digital Health Series – IP for Digital Health technologies

  • Kirsty Simpson presenting at Oxford Global Cell UK pre-event

  • BioForward 2021

  • BioTrinity Conference 2021

  • BIO Korea 2021

  • An antidote to antibody patent confusion in Europe

  • Venner Shipley’s world leading inflammasome client, Inflazome, acquired by Roche

  • G3/19: EBA finds plants produced by essentially biological processes are not patentable